Literature DB >> 17217086

Pharmacogenetics: it's not just about ivermectin in collies.

Patricia Dowling1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17217086      PMCID： PMC1636591     

Source DB:  PubMed          Journal:  Can Vet J        ISSN： 0008-5286            Impact factor:   1.008


× No keyword cloud information.
  7 in total

1.  Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation.

Authors:  Rosemary A Henik; Heidi B Kellum; Steven A Bentjen; Katrina L Mealey
Journal:  J Vet Intern Med       Date:  2006 Mar-Apr       Impact factor: 3.333

2.  Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.

Authors:  K L Mealey; S A Bentjen; J M Gay; G H Cantor
Journal:  Pharmacogenetics       Date:  2001-11

Review 3.  Therapeutic implications of the MDR-1 gene.

Authors:  K L Mealey
Journal:  J Vet Pharmacol Ther       Date:  2004-10       Impact factor: 1.786

4.  Loperamide poisoning in the dog.

Authors:  C Hugnet; J L Cadore; F Buronfosse; X Pineau; T Mathet; P J Berny
Journal:  Vet Hum Toxicol       Date:  1996-02

5.  Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage.

Authors:  Mark W Neff; Kathryn R Robertson; Aaron K Wong; Noa Safra; Karl W Broman; Montgomery Slatkin; Katrina L Mealey; Niels C Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

6.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors:  A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

7.  Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.

Authors:  Katrina L Mealey; Nicole C Northrup; Steven A Bentjen
Journal:  J Am Vet Med Assoc       Date:  2003-11-15       Impact factor: 1.936
  7 in total
  6 in total

1.  Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs.

Authors:  Camilo Romero-Núñez; Linda G Bautista-Gómez; Galia Sheinberg; Alberto Martín-Cordero; Ariadna Flores-Ortega; Rafael Heredia-Cárdenas
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

Review 2.  Broadening the range of use cases for ivermectin - a review of the evidence.

Authors:  Christian Kositz; John Bradley; Harry Hutchins; Anna Last; Umberto D'Alessandro; Michael Marks
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-03-02       Impact factor: 2.455

3.  Safety of oral afoxolaner formulated with or without milbemycin oxime in homozygous MDR1-deficient collie dogs.

Authors:  Marlene Drag; Eric Tielemans; Elizabeth Mitchell
Journal:  J Vet Pharmacol Ther       Date:  2022-05-10       Impact factor: 1.567

Review 4.  Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.

Authors:  Carlos Chaccour; Felix Hammann; N Regina Rabinovich
Journal:  Malar J       Date:  2017-04-24       Impact factor: 2.979

5.  Frequency of the MDR1 mutant allele associated with multidrug sensitivity in dogs from Brazil.

Authors:  Marina M Monobe; João P Araujo Junior; Kari V Lunsford; Rodrigo C Silva; Camilo Bulla
Journal:  Vet Med (Auckl)       Date:  2015-04-13

Review 6.  Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.

Authors:  Anusha Amaravathi; Janet L Oblinger; D Bradley Welling; A Douglas Kinghorn; Long-Sheng Chang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.